Shares of Ultragenyx Pharmaceutical Inc. (RARE) are down 35% from their 52-week high of $60.37, recorded last September, and trade around $39.
This biopharmaceutical company is focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases. It has 4 commercial products - Crysvita for the treatment of X-linked hypophosphatemia, or XLH, and tumor-induced osteomalacia, or TIO; Mepsevii for the treatment of mucopolysaccharidosis VII, or MPSVII or Sly Syndrome; Dojolvi for the treatment of long-chain fatty acid oxidation disorders, or LC-FAOD; and Evkeeza for the treatment of homozygous familial hypercholesterolemia, or HoFH.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com